Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HLSQ with free AI briefings, catalyst countdowns, and dilution alerts.

HLSQ · Tessera Defense & Homeland Security Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$572,000 Cash on Hand
0.5mo Cash Runway
Follow HLSQ by email Get an email when HLSQ reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HLSQ, unsubscribe in one click. Privacy

📣 What HLSQ Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
TSRA-196 Alpha-1 Antitrypsin Deficiency (AATD) Phase 1/2 · NCT07227207 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HLSQ holds $572,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $3.3M/quarter from operations, an estimated runway of 0.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HLSQ files for a raise →

👥 Who Owns HLSQ

Insiders 17.1% Other 5%+ holders 11.3% Institutions (8 holders) 0.5% Public and other holders 71.1%
HolderTypeShares% of sharesAs of
James E Flynn
Director · +3.20M options
Insider 2,494,108 9.33% 2025-02-27
Cystic Fibrosis Foundation
10% owner · +13,088 options
Insider 1,787,758 6.69% 2024-07-15
Menachem Shalom 5%+ holder (13D) 1,600,000 5.99% 2026-04-10
Mandragola Ltd. 5%+ holder (13G) 553,800 2.07% 2026-04-13
Ram Naim 5%+ holder (13D) 477,600 1.79% 2026-09-30
Pyu Pyu Capital, LLC 5%+ holder (13D) 381,422 1.43% 2025-12-26
Jonathan Eitan Solomon
Chief Executive Officer, Director · +4.19M options
Insider 126,748 0.47% 2025-04-14
Merav Bassan
Chief Development Officer · +1.05M options
Insider 79,597 0.30% 2025-04-14
Marina Wolfson
Chief Financial Officer · +1.05M options
Insider 68,545 0.26% 2025-04-14
Assaf Oron
Chief Business Officer
Insider 25,804 0.10% 2024-09-16

Share count 26,723,870 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HLSQ picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HLSQ and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.